| IL223206A0 (en) | | Vaccine formulations |
| IL221409A0 (en) | | Abuse-resistant formulations |
| PL2468361T3 (en) | | Vildagliptin Formulations |
| PL2359816T3 (en) | | Aripiprazole formulations |
| ZA201300194B (en) | | Formulations |
| GB201110193D0 (en) | | Formulations |
| GB201013513D0 (en) | | Formulations |
| GB201110278D0 (en) | | Formulations |
| ZA201300196B (en) | | Formulations |
| GB201006326D0 (en) | | Formulation |
| GB201018649D0 (en) | | Formulations |
| GB201012589D0 (en) | | Formulations |
| GB201018645D0 (en) | | Formulations |
| GB201018647D0 (en) | | Formulations |
| GB201010494D0 (en) | | Formulations |
| GB201008470D0 (en) | | Formulations |
| GB201008358D0 (en) | | Formulations |
| GB201007959D0 (en) | | Formulations |
| GB201007702D0 (en) | | Formulations |
| GB201018648D0 (en) | | Formulations |
| GB201005587D0 (en) | | Novel formulations |
| GB201002000D0 (en) | | Formulation |
| GB201001978D0 (en) | | Formulation |
| GB201005992D0 (en) | | Formulation |
| GB201111578D0 (en) | | Pharmeutical formulations |